Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunder Mudaliar

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Expert Opinion on Drug Safety|February 24, 2010
Pioglitazone: side effect and safety profilePriya Shah, Sunder Mudaliar
Diabetes Technology & Therapeutics|February 25, 2016
The Effects of Aging on Hemoglobin A1c Levels--The Potential Role of the Glycemic GapSindura Alloju, Sunder Mudaliar
The American Journal of Medicine|March 9, 2010
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial functionSunder Mudaliar, Robert R Henry
The American Journal of Medicine|May 26, 2009
Incretin therapies: effects beyond glycemic controlSunder Mudaliar, Robert R Henry
Diabetes Technology & Therapeutics|July 10, 2007
Inhaled insulin in patients with asthma and chronic obstructive pulmonary diseaseSunder Mudaliar, Robert R Henry
European Journal of Internal Medicine|July 8, 2009
Incretin therapies: effects beyond glycemic controlSunder Mudaliar, Robert R Henry
Current Diabetes Reviews|December 22, 2012
Evolution of exenatide as a diabetes therapeuticSunil Bhavsar, Sunder Mudaliar, Alan Cherrington
Current Diabetes Reports|November 24, 2020
Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the BadPreethika Ekanayake, Christopher Hupfeld, Sunder Mudaliar
The Journal of Clinical Endocrinology and Metabolism|January 29, 2021
SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel HypothesisSunder Mudaliar, Christopher Hupfeld, Daniel L Chao
Diabetes Care|June 12, 2016
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying HypothesisSunder Mudaliar, Sindura Alloju, Robert R Henry
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Expert Opinion on Drug Safety|February 24, 2010
Pioglitazone: side effect and safety profilePriya Shah, Sunder Mudaliar
Diabetes Technology & Therapeutics|February 25, 2016
The Effects of Aging on Hemoglobin A1c Levels--The Potential Role of the Glycemic GapSindura Alloju, Sunder Mudaliar
The American Journal of Medicine|March 9, 2010
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial functionSunder Mudaliar, Robert R Henry
The American Journal of Medicine|May 26, 2009
Incretin therapies: effects beyond glycemic controlSunder Mudaliar, Robert R Henry
Diabetes Technology & Therapeutics|July 10, 2007
Inhaled insulin in patients with asthma and chronic obstructive pulmonary diseaseSunder Mudaliar, Robert R Henry
European Journal of Internal Medicine|July 8, 2009
Incretin therapies: effects beyond glycemic controlSunder Mudaliar, Robert R Henry
Current Diabetes Reviews|December 22, 2012
Evolution of exenatide as a diabetes therapeuticSunil Bhavsar, Sunder Mudaliar, Alan Cherrington
Current Diabetes Reports|November 24, 2020
Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the BadPreethika Ekanayake, Christopher Hupfeld, Sunder Mudaliar
The Journal of Clinical Endocrinology and Metabolism|January 29, 2021
SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel HypothesisSunder Mudaliar, Christopher Hupfeld, Daniel L Chao
Diabetes Care|June 12, 2016
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying HypothesisSunder Mudaliar, Sindura Alloju, Robert R Henry
Pageof 9